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Abstract: A series of cyclometallated gold(III) complexes supported by pyrazine-based 
(C^Npz^C)-type pincer ligands were synthesized via two different pathways. Nucleophilic 
attack on the isocyanide complex [(C^Npz^C)Au(C≡NC6H3Me2-2,6)]SbF6 (2) gave 
[(C^Npz^C)Au(ACC)]SbF6 complexes with aniline (4·SbF6), adamantylamine (5), glycine 
ethyl ester (6), alanine methyl ester (7), valine methyl ester (8), phenylglycine methyl ester 
(9) and methionine methyl ester (10) substituents (ACC = acyclic carbene). The pathway via 
isocyanide insertion into gold-amide bonds was also investigated; e.g. the reaction of xylyl 
isocyanide with (C^Npz^C)AuNHPh followed by protonation with HBF4·OEt2 gave the 
acyclic carbene complex 4·BF4. To the best of our knowledge compounds 6 - 10 represent 
the first examples of gold(III) acyclic carbene complexes bearing amino acid functions. The 
compounds provide a versatile platform for the study of anti-proliferative properties of 
gold(III) complexes. Tests against human adenoma-type lung cancer cells identified 5, 6, 7 
and 10 as particularly promising and demonstrate the synthetic flexibility of acyclic carbene 
complexes and the potential of that class of compounds for anticancer applications. 
Compared to cisplatin, amino ester-containing ACC complexes showed improved selectivity 
for MCF-7 breast cancer cells over healthy fibroblasts.  
 
Introduction 
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Since the late 1970s cis-diamminedichloroplatinum(II) (cisplatin)1 has become one of 
the most widely used compounds in the clinic for the treatment of various type of cancer 
including ovarian, testicular, bladder cancer, melanoma, non-small cell lung cancer, small 
cell lung cancer, lymphomas and myelomas.2 Since the introduction of cisplatin only two 
other platinum-based compounds (carboplatin and oxaliplatin) have received worldwide 
approval as anticancer drugs.3 However, despite their clinical success, platinum-based 
metallodrugs present major drawbacks such as a limited spectrum of action, acquired 
resistance to treatment, as well as severe side effects limiting administrable doses to patients.4 
For these reasons, alternatives are being sought, and organometallic gold(I/III) complexes 
have demonstrated promising anticancer properties.5 Indeed, complexes presenting N-
heterocyclic carbene (NHC) ligands, alkynyl ligands and cyclometallated arylpyridine ligands 
give rise to Au(I/III) complexes which are very stable in physiological environments. Special 
interest has focused on cyclometallated complexes in which the Au(III) centre is stabilized by 
(C^N), (C^N^N) or (C^N^C) pincer ligands.5b,6 These complexes tolerate a broad range of 
ancillary ligands such as phosphines,7,8 NHCs,9 or N-donor ligands,10,11 which enables 
optimization of the biological properties of these complexes. The cytotoxicity of some of 
these gold complexes has been demonstrated to be due to the inhibition of various enzymes 
such as thioredoxin reductase (TrxR), poly-(adenosine diphosphate (ADP)-ribose) 
polymerase 1 (PARP-1) and aquaporins.12 Gold(I/III) complexes have also been shown to 
stabilize the G-quadruplex structure of DNA.13 Post-metallation modifications have appeared 
as a very efficient and high-yielding method of introducing elaborated scaffolds into metal 
complexes, for example for derivatising metal gold complexes with peptides,14 aptamers15 or 
other metal complexes.16  
The first gold(III) acyclic carbenes were reported in the 1970s by Balch et al. and 
Minghetti and co-workers.17,18 The compounds were described to behave as oxidising agents. 
Further early work on gold(III) open-carbene systems by Usón and Villacampa et al. 
describes the synthesis of mononuclear, mono-carbene gold(III) complexes.19 The authors 
utilised existing synthetic methodology, reacting primary amines or diamines with gold(III) 
isocyanide complexes to produce acyclic carbene complexes. Since then few investigations 
on these systems have been reported, except for a small number of papers describing 
cyclometallated gold(III) carbenes produced either by insertion of an isocyanide into an Au-N 
bond20,21 or by nucleophilic attack of a gold-CNR complex by an amine.22 We became 
interested in acyclic carbene complexes since their formation promised to present a simple 
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way of functionalizing gold complexes with bio-inspired moieties bearing a amine functions 
such as amino acid derivatives. 
 
Fig. 1 Structures of previously reported Au(III) conjugates with amino acid derivatives and of 
the benzimidazolylidene complex AuNHC. 
 
As we have recently reported, pyrazine-based pincer complexes23 with 
benzimidazolylidene ligands [(C^Npz^C)Au(NHC)]+ (AuNHC, Fig. 1) possess promising 
anticancer properties against human leukemia, breast cancer and lung cancer cells.24 
However, although the compounds showed lower toxicity against healthy lung fibroblasts, 
the selectivity of the compound for cancer cells needs to be improved. Considering the high 
stability of the [(C^Npz^C)Au(carbene)]+ scaffold under physiological conditions, including 
their tolerance to increased concentrations of glutathione (GSH), the attachment of a potential 
vector via the carbene ligand seemed attractive in the search for improving target selectivity.  
In recent years, coupling of organometallics to peptides has appeared as a promising 
way to increase their selectivity to cancer cells.25 This concept has been applied 
predominantly to gold(I) complexes using mono- or polypeptide vectors.26 Although some 
examples of Au(III) complexes conjugated to amino acid derivatives have been reported (Fig. 
1),26a,c,f,27 to the best of our knowledge no examples of cyclometallated Au(III) complexes 
bearing amino acid moieties have been synthesized so far. Within this context, we report here 
the synthesis and characterization of the first cyclometallated Au(III) complexes decorated 
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with amino ester-based acyclic diamino carbene (ACC) ligands. The compounds were 
screened for their antiproliferative properties against a human lung cancer cell line (A549). 
The most promising ones were then tested against a broader panel of human cancer cells, 
including lung adenocarcinoma (A549), leukemia (HL60), colon cancer cells (HCT116), 
breast cancer cells (MCF-7 and MDA-MB-231), as well as healthy fibroblasts (MRC5) for 
comparison. 
 
Results and Discussion 
Synthesis and characterization. Following reported procedures,17-19 we started by 
exploring the amine attack on cationic gold(III) isocyanide complexes, which seemed the 
most promising route to the expected amino-acid derivatised acyclic carbene complexes. 
Treatment of (C^Npz^C)AuCl (1) with 2,6-Me2C6H3N≡C and AgSbF6 under strictly 
anhydrous conditions gave the isocyanide complex 2 in good yield (Scheme 1). The synthesis 
of 2 was confirmed by NMR and IR spectroscopy and elemental analysis. The 1H and 13C 
NMR signals were assigned and confirmed with HMQC experiments. The IR spectrum 
showed a weak ν(C≡N) signal at 2267 cm-1. This value is in good agreement with previously 
reported [(C^N^C)AuCNR]+ complexes.28 Complex 2 appeared to be very sensitive to 
hydrolysis and in the presence of moisture readily formed the formamide complex 3, with 
characteristic IR bands of ν(NH) = 3296 cm-1 and ν(C=O) = 1643 cm-1.  
Complex 2 was reacted with dry, distilled aniline at room temperature to give the 
corresponding acyclic diamino carbene complex 4·SbF6 in good yield (Scheme 1). The 
complex displays two NH peaks in the 1H NMR spectrum, at δ 9.7 and 9.4 ppm. The ν(C=N) 
stretching frequency of 4·SbF6 is found at 1586 cm
-1. The reaction of 2 with adamantylamine 
gave compound 5, which shows an up-field shift of the characteristic H2 peak to 8.9 ppm and 
the appearance of broad 1H NMR singlets for the NH moieties at 8.3 and 6.6 ppm. The 
chemical shift difference is much larger than in 4·SbF6, illustrating the difference between 
the aryl and alkyl amine substituents of the carbene. The IR spectrum of 5 shows the 
characteristic νC=N(carbene) band at 1585 cm
-1, together with two distinct ν(NH) bands of the 
carbene at 3312 cm-1 and 3210 cm-1. The [(C^Npz^C)Au(ACC)]+ complexes are very stable 
even in solution, which contrasts with recent reports on (ACC)AuCl3 complexes.
29  
The reaction of the amino esters Gly-OEt, Ala-OMe, Val-OMe, PhGly-OMe and Met-
OMe with 2 afforded the corresponding amino ester complexes 6-10 in good yields. All 
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complexes feature the ν(carbene) band at 1585 cm-1 in their IR spectra, along with a ν(C=O) 
band at ~1740 cm-1. While the 1H and 13C{1H} NMR spectra of 6, which contains a non-
chiral glycine moiety, reflected the mirror symmetry of the (C^Npz^C) pincer ligand, the 1H 
and 13C{1H} NMR spectra of 7-10 showed the loss of lateral symmetry of the (C^Npz^C) 
framework, indicated by a doubling of the tert-butyl, H5, H8 and CH3(xylyl) signals. The 
effect is most prominent in the spectra of 8 and 9, which contain the sterically most 
demanding side chains. The NMR spectra were fully assigned using HMQC and HMBC 
NMR experiments. 
 
Scheme 1 Synthesis of (C^Npz^C)Au complexes 2-10.  
 
 The alternative pathway, the insertion of isocyanides into the gold-amide bond, was 
also briefly explored. The reaction of 1 with anilines in the presence of base afforded 11a, b 
in high yields (Scheme 2). Both complexes 11a and 11b were reacted with 2,6-
dimethylphenylisocyanide at room temperature overnight. 11a gave the corresponding 
insertion product 12 in good yield, whereas 11b, with the more bulky 2,6-diisopropylaniline 
ligand, did not react and returned the unreacted starting material. NMR analysis of compound 
12 revealed the presence of a NH proton at 6.71 ppm in the 1H NMR spectrum and a signal at 
124.7 ppm in the {1H}13C corresponding to the inserted carbon. The formation of 12 was 
confirmed by the IR spectrum which showed the NH vibration at 3340 cm-1 and the C=N 
stretch at 1607 cm-1. Insertion of tert-butyl isocyanide and cyclohexyl isocyanide into 11a 
was attempted in a variety of reaction conditions. Tert-butyl isocyanide inserted as expected 
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but promptly rearranged to produce the cyanide complex, as was previously noticed for 
pyridine-based complexes.27 Cyclohexyl isocyanide generated a mixture of products which 
proved impossible to separate and purify. Protonation of 12 using HBF4OEt2 produced the 
air-stable carbene complex 4·BF4, with the same spectroscopic characteristics as its SbF6 
analogue 4·SbF6.  
N
N
tBu tBuAu
Cl
N
N
tBu tBuAu
HNNH2
R
R
1) KOtBu
toluene,
RT, 3 h
2) 
toluene, 
RT 3 h
R
R
11a: R = H, 91 %
11b: R = iPr, 74 %
1
toluene,
RT 16 h
83%
NC
12 4.BF4
HBF4.Et2O, 
Et2O
-78 oC to RT 
30 min
+
BF4
-
N N
tBu
tBu
Au
N
NH
N N
tBu
tBu
Au
NH
NH
100%
 
Scheme 2 Synthesis of acyclic carbene 4·BF4 from gold(III) anilide.  
 
Solid state structures. The crystal structures of 2, 3, 5·1.5 toluene, 6, 11a and 12·toluene 
were determined by X-ray diffraction. Selected views of the structures and distances and 
angles of 5·1.5 C7H8 and 6 are shown in Fig. 2; views of the molecular and packing structures 
of all other compounds are given in the ESI. In all cases, the square-planar geometry of the 
AuIII centres is distorted due to the strain induced by the bis-cyclometallated C^N^C ligand. 
 
Fig. 2 (a) Crystal structure of complex 5·1.5 C7H8. Ellipsoids set at 50% probability. Toluene 
molecules are omitted for clarity. Selected bond distances [Å] and angles [°]: Au-N1 2.01(1), 
Au-C7 2.03(1), Au-C22 2.10(1), Au-C62 2.09(1), N1-Au-C7 175.8(4), N1-Au-C22 80.4(4), 
N1-Au-C62 80.5(4), C22-Au-C7 101.6(5), C62-Au-C7 97.4(4), C22-Au-C62 160.9(4). (b) 
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Structure of 6. Ellipsoids set at 50% probability. Selected bond distances [Å] and angles [°]: 
Au-N1 2.012(2), Au-C25 2.010(3), Au-C6 2.098(3), Au-C16 2.102(3), N1-Au-C25 177.0(1), 
C6-Au-C16 160.8(1), N1-Au-C6 80.6(1), N1-Au-C16 80.3(1), C6-Au-C25 98.8(1), C16-Au-
C25 100.4(4), N3-C25-N4 118.5(3). 
 
The distances and angles in the C^Npz^CAu moiety are comparable to those described 
previously.23,29,30 In the neutral amidate complexes 3 and 12 the Au-C7/C25 distances of 
2.0251(18) and 2.031(4) Å, respectively, are comparable to the Au-C σ-bond distances in 
gold alkyls, typically in the range 2.00-2.15 Å.23,30,31 
In the cationic AuIII-carbene complexes the Au-C7/C25 distances (2.037(11) Å 5, 
2.010(3) Å 6) are in the upper range of distances observed for complexes of cyclic carbenes 
[(C^N^C)Au(NHC)]+ (1.967 to 2.017 Å),23,32 possibly due to a combination of steric 
hindrance and lower donor strength of the acyclic carbenes. The carbene adopts an almost 
perfectly perpendicular orientation relative to the (C^Npz^C)Au plane [torsion angles C22-
Au-C7-N8 90.7(8) in 5, and C6-Au-C25-N3 90.9(3) in 6], in contrast with the value of 115-
120º found in [(C^Npz^N)Au(1,3-dimethylbenzimidazol-2-ylidene)]PF6.
24  
This conformation of the carbene allows the formation of supramolecular interactions. 
As we showed recently, pyrazine-based pincer complexes have a tendency to aggregate 
through the formation of π···π interactions that involve the pyrazine rings.33 In the present 
complexes, however, the presence of N-H protons in the ancillary ligand and the formation of 
intermolecular H···Npz interactions are the main driving force for aggregation. Fig. 3 shows 
illustrative examples (see ESI for further details of intermolecular interactions of 2, 3, 5, 11a 
and 12 in the solid state).  
As can be seen in Figs. 3a and 3b for complex 6 and Fig. S3 for 5·1.5 C7H8, the carbene 
complexes crystallize as dimers held together by xylylNH···Npz interactions (2.187 Å in 
5·1.5 C7H8; 2.443 Å in 6). There are also C(aryl)H···F interactions with the SbF6 anions. 
Rather than forming a π-stack of the arene rings, the two planar neighbouring (C^N^C)Au 
moieties show a head-to-head alignment of the pyrazine ring of one molecule with the Au-N 
bond of another, with an offset of about 1.15 Å. The formimidate complex 12·C7H8 also 
forms dimers through xylylNH···Npz interaction (2.407 Å). Here, too, the pyrazine ring of 
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one molecule is aligned with the Au-N bond of the second, although in this case the off-set is 
minimal (Fig. 3c).  
The neutral complexes 3 and 11a form polymeric zig-zag chains. In the case of complex 
3 (Fig. 3d) the intermolecular interactions involve again NH···Npz contacts (2.280 Å), as well 
as additional O···H-C interactions between the oxygen atoms of the formamido ligand and 
protons of the pyrazine ring of a neighbouring molecule. In the case of 11a, additional 
interactions contributing to chain formation involve the ortho protons of the phenyl ring of 
the aniline (see ESI, Fig. S4b). 
In the absence of NH functional groups leading to NH···N(pz) interactions, π-stacking 
of the pyrazine rings seems to be preferred, as illustrated by the structure of the isocyanide 
complex 2 (see ESI. Fig. S1b). The presence or absence of such hydrogen bonding patterns is 
likely to be of importance not just for crystal packing arrangements but also for the 
interactions of pyrazine-based functionalised complexes with biomolecules and cells.   
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Fig. 3 (a) Side view of the crystal packing of complex 6, showing the carbene NH···N(pz) 
and CH···F interactions. (b) Top view of the dimer found in the crystal packing of complex 6. 
(c) Top view of the aggregation in Complex 12·C7H8. (d) Side view of the aggregation in 
complex 3. 
 
In vitro antiproliferative activity. Although the complexes proved to be only poorly 
soluble in purely aqueous media, all compounds are soluble enough in DMSO not to 
precipitate when diluted with aqueous buffer solution up to 100 µM with 1% DMSO. An 
initial screening of compounds 1, 3 - 10 and 12 was carried out on human A549 lung 
adenocarcinoma cells. This cell line was chosen for its ability to discriminate efficiently 
between structurally very similar (C^Npz^C)AuIII carbene complexes.24 The inhibition of the 
proliferation of A549 cells was determined using the established MTS assay (see ESI) after 
72 h of incubation with the starting chloride complex 1 and compounds 3 - 10 and 12 at 
concentrations of 100 µM and 10 µM (Fig. 4). Both neutral complexes 3 and 12 did not show 
any antiproliferative effects against A549 cells at both concentrations. This is consistent with 
our previous results using stable neutral (C^N^C)Au complexes bearing phenylacetylide and 
thiophenolate ligands.24 The acyclic diamino carbene complexes 4·SbF6 and 4·BF4 (featuring 
an aniline substituent) demonstrated only poor antiproliferative effects on the tested cell line. 
Although the cell viability when treated with 4·SbF6 was noticeably lower than when treated 
with 4·BF4 at 100 µM concentration (cell viability of 38 % and 65 % for 4·SbF6 and 4·BF4, 
respectively), at a concentration of 10 µM no difference was observed, indicating that the 
SbF6 anion has only a marginal effect on the antiproliferative properties of the compounds at 
low concentrations.  
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 Fig. 4  Inhibition of A549 cells growth by complexes 1, 3 - 10 and 12 in DMSO; data 
represent the average ± standard error of three experiments.  
 
Complexes 5 - 10 all inhibited A549 cell proliferation at a concentration of 100 µM. 
However, of those only 5 - 7 and 10 showed a cell viability of A549 cells below 50 % at 10 
µM (cell viability of 9.6 %, 38.4 %, 14.9 % and 23.5 % for 5, 6, 7 and 10, respectively). The 
two complexes with the most lipophilic side-chains (isopropyl for 8, and phenyl for 9) turned 
out to have a reduced activity compared to the other amino ester decorated 
[(C^Npz^C)Au(ACC)]X complexes.  
The four complexes which inhibited cell proliferation by more than 50 % at 10 µM 
concentration were selected for the determination of the IC50 values (i.e. the concentration 
required to inhibit 50 % cell growth) on a panel of human cell lines, including (i) solid 
tumour cells, that is human lung (A549), breast (MCF-7) and colon (HCT-116) 
adenocarcinomas; (ii) breast adenocarcinoma (MDA-MB-231) as an example of highly 
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metastatic cancer cells; (iii) leukemia (HL60) as an example of suspension cells; and (iv) 
healthy fibroblasts (MRC-5). The results are reported in Table 1. 
 
Complexes 5 - 7 and 10 all showed significantly higher cytotoxicity than cisplatin 
against A549, MCF-7 and MDA-MB-231 cells, while only the adamantyl derivative 5 was 
more toxic than cisplatin against HL60 and HCT-116 cells. In particular, the new compounds 
show promising antiproliferative effects against A549, MCF-7 and MDA-MB-231 cells, 
which are cell lines with the least sensitivity towards cisplatin, and which are the most 
difficult to treat. Overall the activity is similar to that of our benzimidazole-based compound 
AuNHC.24    
The adamantyl compound 5 was over ten times more potent than AuNHC against 
HCT-116 and MBA-MB-231 cells. Among the series of amino ester derivatives, the glycine-
based complex 6 appeared as the least toxic in the series. Overall, the low micromolar 
activities of the [(C^Npz^C)Au(ACC)]X complexes, including against A549, MCF-7 and 
MDA-MB-231 cell lines which show only poor sensitivity towards cisplatin, render them 
promising for the development of anticancer drugs. Complexes 6, 7 and 10 appeared to have 
a reduced activity against the healthy fibroblasts compared to the heterocyclic complex 
AuNHC. Indeed, all amino ester-containing complexes compounds 6, 7, 10 and AuNHC 
show improved selectivity for MCF-7 cells versus MRC-5 fibroblasts (selectivity factor 
Table 1: Effects of compounds 5-7, 10, AuNHC and cisplatin on cell viability of a panel of 
human cancer cell lines and of healthy fibroblast MRC-5 cells after 72 h incubation. 
Complex 
IC50 ± SD (µM)
a
 
SMCF7/MRC5 
A549 MCF-7 HL60 
HCT-
116 
MDA-
MB-231 
MRC-5 
5 6.1 ± 1.1 5.2 ± 0.2 
0.8 ± 
0.1 
0.6 ± 
0.1 
0.3 ± 0.1 
0.37 ± 
0.03 
0.07 
6 13.0 ± 3.6 6.4 ± 1.6 
16.7 ± 
2.5 
8.4 ± 
0.5 
5.1 ± 2.0 8.8 ± 1.0 1.4 
7 7.9 ± 1.5 3.9 ± 0.6 
8.1 ± 
0.9 
8.1 ± 
0.4 
4.7 ± 0.7 6.9 ± 1.1 1.8 
10 7.7 ± 1.6 3.4 ± 0.2 
6.9 ± 
0.6 
7.3 ± 
0.4 
11.1 ± 
2.8 
6.4 ± 0.7 1.9 
AuNHC
 7.8 ± 1.3b 
0.56 ± 
0.02b 
0.3 ± 
0.1b 
11.2 ± 
1.5 
5.7 ± 0.4 
1.4 ± 
0.4b 
2.5 
Cisplatin
 33.7 ± 
3.7b 
21.2 ± 
3.9b 
3.7 ± 
0.3b 
5.3 ± 
0.2 
28.4 ± 
0.1 
10.7 ± 
3.0b 
0.5 
aMean ± standard error of at least three independent experiments. b Values from ref. 24. 
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SMCF7/MRC5 >1) and proved significantly more selective than cisplatin (SMCF7/MRC5 = 0.5). Only 
the adamantyl compound 5 is less selective).  
  
Reactive oxygen species quantification. Inducing the formation of reactive oxygen 
species (ROS) is a well-known mechanism of action of metal-based drugs and especially of 
Au(I)-NHC complexes.34 Our panel of acyclic carbene complexes was therefore tested in this 
respect. We measured the amount of intracellular ROS after treatment of A549 cells with 100 
µM, 50 µM and 10 µM concentrations of the four toxic complexes 5 - 7 and 10 and the non-
toxic complex 4·SbF6 as negative control (see Experimental for details). The results are 
summarized in Fig. 5. We observed no particular increase in ROS formation for any of the 
tested complexes, including the cytotoxic ones. These data suggest therefore that induction of 
ROS is unlikely to be the cause of cytotoxicity, and this mode of action can therefore be ruled 
out for this class of compounds.  
 
Fig. 5 ROS measurement in A549 cells after 24 h incubation with complexes 4·SbF6, 5 - 7 
and 10.  
 
Reaction with glutathione. Glutathione (GSH) is a tripeptide present at millimolar levels 
inside cells and is found overexpressed in most cancer cells. GSH is involved in many 
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different cellular functions such as xenobiotic detoxification and reactive oxygen species 
(ROS) scavenging.35 Moreover, GSH has been related to resistance mechanism to cisplatin.36 
Although GSH is known to reduce Au(III) complexes bearing (N^N) or (N^N^N) chelating 
ligands,37 we demonstrated the stability of bis-cyclometallated Au(III)-NHC complex toward 
reduction and substitution with GSH.24 We have therefore explored the reactivity of GSH 
towards two representative complexes, 6 and 7, by 1H NMR spectroscopy. Both 6 and 7 were 
mixed at room temperature with GSH in DMSO-d6/D2O 1/1 over a period of time of 24 h 
(Fig. 6 and S6). Although neither 6 nor 7 showed any reaction with GSH over the first hour, 
over 24 h we observed the formation of oxidized glutathione (GSSG), the disappearance of 
the signals of the [(C^N^C)Au(III)(ACC)]+ cations and the formation of a pale yellow product, 
which we tentatively attribute to the reduction product (C^N^CH)Au(I)(ACC).  This leads to 
the conclusion that acyclic carbene complexes are more sensitive to GSH than 
benzimidazole-type Au(III) carbene adducts.24 
 
Figure 6: 1H NMR spectra of a 1/1 mixture of 6 with GSH at different reaction times at room 
temperature, and comparison with the starting materials 6, GSH and GSSG(DMSO-d6/D2O 
1/1).  
Conclusion 
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We have reported the synthesis and characterization of thirteen new pyrazine-based 
cyclometallated (C^Npz^C)AuIII complexes, including the first cyclometallated AuIII 
complexes decorated with amino acid derivatives. Gold(III) complexes of acyclic carbene 
ligands are readily synthesized and easily modified, including the introduction of 
biomolecules such as amino acids. The nucleophilic attack on gold(III) isocyanide complexes 
proved to be the most efficient pathway and is exemplified here by the synthesis of five 
amino ester decorated  [(C^Npz^C)Au(ACC)]X complexes. The crystal structures of these 
complexes showed the importance of hydrogen bonding involving the non-coordinated 
pyrazine-N atom as a major tool for organising intermolecular interactions. The 
antiproliferative screening on A549 cells of ten (C^Npz^C)AuIII pincer complexes revealed 
compounds 5 - 7 and 10 as the most promising candidates, highlighting the usefulness of 
acyclic carbene ligands as well as the effect of the amino ester substituents. While the 
antiproliferative mode of action of these complexes remains largely a matter of conjecture, 
tests can be applied so that certain pathways can be ruled in or out. In the present case, it 
could be established that reactive oxygen species (ROS) are not enhanced by these 
compounds and are unlikely to play a role in inducing cell death. Studies are continuing to 
investigate possible modes of action of acyclic carbene complexes of gold in the search for 
enhanced cell selectivity.  
Experimental Section 
When required, manipulations were performed using standard Schlenk techniques under dry 
nitrogen or in an MBraun glove box. Nitrogen was purified by passing through columns of 
supported P2O5 with moisture indicator, and activated 4 Å molecular sieves. Anhydrous 
solvents were freshly distilled from appropriate drying agents. 1H and 13C{1H} spectra were 
recorded using a Bruker Avance DPX-300 spectrometer. 1H NMR spectra (300.13 MHz) 
were referenced to the residual protons of the deuterated solvent used. 13C{1H} NMR spectra 
(75.47 MHz) were referenced internally to the D-coupled 13C resonances of the NMR 
solvent. Elemental analyses were carried out at London Metropolitan University. Compound 
1 has been synthesized following reported procedures.23  
 
Synthesis of [(C^N
pz
^C)Au(2,6-dimethylphenyl isocyanide)]SbF6 (2)  
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Under an N2 atmosphere, 1 (0.150 g, 0.261 mmol), 2,6-dimethylphenylisocyanide (0.041 g, 
0.313 mmol), AgSbF6 (0.107 g, 0.313 mmol) and a few pellets of 4A molecular sieves were 
placed in a flame-dried Schlenk flask and dichloromethane was added (15 mL). The mixture 
was left to stir at room temperature for 4 h. A white precipitate of AgCl was removed by 
filtration through celite, and the filtrate collected under an N2 atmosphere. The solvent was 
evaporated to a minimum and the product precipitated with an excess of light petroleum (bp. 
40-60 °C). The supernatant was removed and the residue dried under vacuum to yield a 
yellow solid (0.198 g, 84 %). Anal. Calcd. for C33H35AuN3SbF6 (906.4): C, 43.73; H, 3.89; 
N, 4.64. Found: C, 43.84; H, 3.69; N, 4.75. 1H NMR (CD2Cl2, 300 MHz, 298 K): δ 8.93 (s, 
2H, H2), 7.89 (d, 3J = 1.80 Hz, 2H, H8), 7.77 (d, 3J = 8.25 Hz, 2H, H5), 7.59 (t, 3J = 7.47 Hz, 
1H, CHpara), 7.53 (dd, 3J = 8.28 Hz, 4J = 1.8 Hz, 2H, H6), 7.42 (d, 3J = 7.86 Hz, 2H, CHmeta), 
2.73 (s, 6H, CH3
xylyl), 1.36 (s, 18H, tBu). 13C{1H} NMR (CD2Cl2, 75 MHz): δ 168.1 (s, C
9), 
159.5 (s, C4), 158.4 (s, C7), 143.8 (s, C3), 140.2 (s, C2), 137.5 (s, Cortho), 134.4 (s, C8), 133.6 
(s, CHmeta), 129.6 (s, CHpara), 127.6 (s, C5), 126.7 (s, C6), 36.2 (s, C(CH3)3), 31.1 (s, C(CH3)3), 
19.4 (s, CH3
xylyl). IR: νmax (neat)/cm
-1: 2957 (CH), 2267 (C≡N). 
 
Synthesis of [C^N
pz
^C]Au(2,6-dimethylphenyl formamide) (3) 
A mixture of 2 (0.055 g, 0.061 mmol) and K2CO3 (0.025 g, 0.182 mmol) dissolved in a 
mixture of THF (5 mL) and water (2 mL) was stirred at room temperature for 3 h. The THF 
was removed under vacuum and water (10 mL) was added. The product was extracted using 
dichloromethane (3 × 10 mL) and the organic layer washed with water (3 × 10 mL) and dried 
with anhydrous Na2SO4. The solution was evaporated and the solid residue washed twice 
with light petroleum (bp. 40-60 °C) and dried, to yield a bright yellow solid (0.038 g, 68 %). 
Anal. Calcd. for C33H36AuN3O (687.6): C, 57.64; H, 5.28; N, 6.11. Found: C, 57.42; H, 5.18; 
N, 6.19. 1H NMR (CD2Cl2, 300 MHz, 298 K): δ 8.80 (s, 2H, H
2), 8.00 (d, 3J = 2.01 Hz, 2H, 
H8), 7.60 (d, 3J = 8.16 Hz, 2H, H5), 7.33 (dd, 3J = 2.07 Hz, 4J = 8.16 Hz, 2H, H6), 7.16 (s, 3H, 
CHxylyl), 7.07 (s, 1H, NH), 2.50 (s, 6H, CHxylyl), 1.34 (s, 18H, tBu). 13C{1H} NMR (CD2Cl2, 
75 MHz): δ 168.8 (s, C10), 167.5 (s, C9), 156.6 (s, C7), 156.4 (s, C4), 144.8 (s, C3), 138.4 (s, 
C
2), 136.7 (s, Cipso), 135.8 (s, Cortho), 134.9 (s, C8), 128.5 (s, CHxylyl), 127.2 (s, CHxylyl), 126.0 
(s, C5), 124.3 (s, C6), 35.7 (s, C(CH3)3), 31.4 (s, C(CH3)3), 19.7 (s, CH3
xylyl). IR: νmax 
(neat)/cm-1: 3296 (NH), 2962 (CH), 1643 (C=O). 
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Synthesis of [(C^N
pz
^C)Au{C(NHPh)(NHC6H3Me2-2,6)}]SbF6 (4·SbF6) 
Complex 2 (0.066 g, 0.073 mmol) and aniline (0.014 g, 0.146 mmol) were combined in a 
flame-dried Schlenk flask, with molecular sieves, under N2 atmosphere, dissolved in 
dichloromethane and filtered through a celite plug. The product was precipitated by addition 
of a 2/1 mixture of light petroleum (bp. 40-60 °C) and diethyl ether. The product was finally 
dried under vacuum to yield a bright yellow solid (0.060 g, 0.050 mmol, 58%). Calcd. for 
C39H42AuF6N4Sb·3H2O (1053.6): C, 44.46; H, 4.59; N, 5.32. Found: C, 44.02; H 4.94; N 
5.25. 1H NMR (CD3CN, 300 MHz, 298 K): δ 9.68 (s, 1H, NH), 9.40 (s, 1H, NH), 8.96 (s, 2H, 
H2), 7.80-7.71 (m, 4H, CHAr), 7.46-7.32 (m, 7H, CHAr), 7.24-7.14 (m, 3H, CHAr), 2.53 (s, 6H, 
CHxylyl), 1.34 (s, 18H, tBu). IR: νmax (neat)/cm
-1: 3311 (NH) , 2958 (CH), 1586 (carbene). 
 
Synthesis of [(C^N
pz
^C)Au{C(NH-1-Ad)(NHC6H3Me2-2,6)}]SbF6 (5) 
Complex 2 (0.050 g, 0.055 mmol) and 1-adamantylamine (0.017 g, 0.110 mmol) were 
combined in a flame-dried Schlenk flask, with molecular sieves, under N2 atmosphere and 
dissolved in dichloromethane (5 mL). The solution was stirred at room temperature for 16 h. 
The product was precipitated with an excess of light petroleum (bp. 40-60 °C), filtered off 
and dried under vacuum to yield a bright yellow solid (0.031 g, 53%). Anal. Cald. for 
C43H52AuN4SbF62H2O (1093.66): C, 47.22; H, 5.16; N, 5.12. Found: C, 47.16; H, 4.71; N, 
5.30. 1H NMR (CD2Cl2, 300 MHz, 298 K): δ 8.89 (s, 2H, H
2), 8.31 (s, 1H, NH), 7.73 – 7.70 
(m, 4H, H5/8), 7.46 (dd, 3J = 1.8 Hz, 4J = 8.30 Hz, 2H, H6), 7.40 – 7.34 (m, 3H, CHxylyl), 6.61 
(s, 1H, NH), 2.51 (s, 6H, CHxylyl), 2.04 (s, 9H, CHad. + CH2
ad.), 1.54 – 1.51 (m, 6H, CH2
ad), 
1.36 (s, 18H, tBu). 13C{1H} NMR (CD2Cl2, 75 MHz): δ 172.4 (s, C
10), 166.5 (s, C9), 157.9 (s, 
C
7), 157.3 (s, C4), 144.5 (s, C3), 139.5 (s, C2), 135.9 (s, Cortho), 134.6 (s, C8), 130.9 (s, 
CHxylyl), 130.5 (s, CHxylyl), 127.0 (s, C5), 125.6 (s, C6), 57.5 (s, Cad.), 44.6 (s, CH2
ad.), 36.0 (s, 
C(CH3)3), 35.6 (s, CH
ad), 31.3 (s, C(CH3)3), 29.8 (s, CH2
ad.), 19.5 (s, CH3
xylyl). IR: νmax 
(neat)/cm-1: 3311 (NH) , 2958 (CH), 1586 (carbene). 
 
[(C^N
pz
^C)Au{C(NHCH2CO2Et)(NHC6H3Me2-2,6)}]SbF6 (6) 
Glycine ethyl ester HCl (0.020 g, 0.146 mmol) was added to a flame-dried Schlenk flask 
charged with K2CO3 (0.012 g, 0.088 mmol) and acetonitrile (10 mL). The solution was 
sonicated for 30 min and transferred to a separate flame-dried Schlenk flask containing 2 
Page 16 of 28Dalton Transactions
D
al
to
n
Tr
an
sa
ct
io
ns
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
11
 S
ep
te
m
be
r 2
01
7.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f E
as
t A
ng
lia
 L
ib
ra
ry
 o
n 
11
/0
9/
20
17
 2
0:
33
:0
0.
 
View Article Online
DOI: 10.1039/C7DT02804K
(0.066 g, 0.073 mmol). The reaction was then stirred for 16 h at room temperature and the 
precipitate removed from solution via filtration through a celite plug. Next, the solvent was 
removed under vacuum and the solid residue re-dissolved in dichloromethane (2 mL). The 
product was crashed out of solution using a 2:1 mixture of light petroleum (bp. 40-60 °C) / 
diethyl ether (5 mL), and after removing the solvent, dried under vacuum to yield a bright 
yellow solid (0.062 g, 0.061 mmol, 59%). Calcd. for C37H44AuF6N4O2Sb (1009.5): C, 44.02; 
H, 4.39; N, 5.55. Found: C, 43.91; H 4.45; N 5.48. 1H NMR (CD3CN, 300 MHz, 298 K): δ 
9.66 (s, 1H, NH), 8.99 (s, 2H, H2), 7.81 (d, 3JH-H = 8.3 Hz, 2H, H
5), 7.70 (d, 4JH-H = 2.0 Hz, 
2H, H8), 7.57 (s, 1H, NH), 7.45 (dd, 3JH-H = 8.3 Hz, 
4
JH-H = 2.0 Hz, 2H, H
6), 7.40 – 7.28 (m, 
3H, CHAr.), 4.25 (d, 3JH-H = 4.3 Hz, 2H, NCH2), 3.97 (q, 
3
JH-H = 7.2 Hz, 2H, OCH2) 2.50 (s, 
6H, CH3
xylyl), 1.33 (s, 18H, tBu), 1.01 (t, 3JH-H =7.2 Hz, 3H, CH3
Et). 13C{H} NMR (CD3CN, 
75 MHz): δ 177.7 (s, C10), 168.2 (s, C=O), 165.2 (s, C9), 156.8 (s, C4), 156.4 (s, C3), 144.9 (s, 
C
7), 139.6 (s, C2), 135.8 (s, Cortho), 133.3 (s, C8), 132.4 (s, Cipso), 129.8 (s, CHxylyl), 129.4 (s, 
CHxylyl), 126.8 (s, C5), 125.0 (s, C6), 61.6 (s, OCH2), 50.0 (s, NCH2), 35.3 (s, C(CH3)3), 30.4 
(s, C(CH3)3), 18.3 (s, CH3
xylyl), 13.3 (s, CH2CH3). IR: νmax (neat)/cm
-1: 3317 (NH), 3171 
(NH), 2963 (CH), 1740 (C=O), 1585 (carbene). 
 
Synthesis of [(C^N
pz
^C)Au{C(NHCH(Me)CO2Me)(NHC6H3Me2-2,6)}]SbF6 (7) 
L-alanine methyl ester HCl (0.020 g, 0.146 mmol) was added to a flame-dried Schlenk flask 
charged with K2CO3 (0.012 g, 0.088 mmol) and acetonitrile (5 mL). The solution was 
sonicated for 30 min and transferred to a separate flame-dried Schlenk flask containing 2 
(0.066 g, 0.073 mmol). The reaction was then stirred for 16 h at room temperature and the 
precipitate removed from solution via filtration through a celite plug. Next, the solvent was 
removed under vacuum and the solid residue re-dissolved in dichloromethane (2 mL). The 
product was crashed out of solution using a 2:1 mixture of light petroleum (bp. 40-60 °C) / 
diethyl ether (5 mL), and after removing the solvent, dried under vacuum to yield a bright 
yellow solid (0.070 g, 0.069 mmol, 67%). Calcd. for C37H44AuF6N4O2Sb (1009.50): C, 
44.02; H, 4.39; N, 5.55. Found: C, 43.92; H 4.37; N 5.46. 1H NMR (CD3CN, 300 MHz, 298 
K): δ 9.40 (s, 1H, NH), 9.00 (s, 2H, H2/2’), 7.85 (d, 3JH-H = 8.3 Hz, 1H, H
5/5’), 7.81 (d, 3JH-H = 
8.3 Hz, 1H, H5/5’), 7.74 (d, 4JH-H = 2.0 Hz, 1H, H
8/8’), 7.70 (s, 1H, NH), 7.66 (d, 4JH-H= 2.0 
Hz, 1H, H 8/8’), 7.49 (dd, 3JH-H = 8.3 Hz, 
4JH-H = 2.0 Hz, 1H, H
6/6’), 7.45 (dd, 3JH-H = 8.3 Hz, 
4JH-H = 2 Hz, 1H, H
6/6’), 7.37-7.27 (m, 3H, CHxylyl), 4.86 (m, 1H, NCH), 3.53 (s, 3H, OCH3), 
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2.58 (s, 3H, CH3
xylyl), 2.44, (s, 3H, CH3
xylyl), 1.39 (d, 3JH-H = 7.2 Hz, 3H, CH3
ala.), 1.32 (s, 9H, 
tBu), 1.32 (s, 9H, tBu). 13C{H} NMR (CD3CN, 75 MHz): δ 176.2 (s, C
10), 170.9 (s, C=O), 
165.2 (s, C9), 164.9 (s, C9’), 157.0 (s, C7), 156.8 (s, C7’), 156.4 (s, C4), 156.3 (s, C4’), 145.0 (s, 
C
3), 144.9 (s, C3’), 139.8 (s, C2), 139.7 (s, C2’), 135.9 (s, Cortho), 135.7 (s, Cortho’), 133.9 (s, 
C
8), 132.9 (s, C8’), 132.4 (s, Cipso), 129.9 (s, CHxylyl), 129.5 (s, CHxylyl), 129.4 (s, CHxylyl), 
127.1 (s, C5), 126.8 (s, C5’), 125.3 (s, C6), 125.1 (s, C6’), 58.6 (s, NCH), 52.6 (s, OCH3), 35.3 
(s, C(CH3)3), 30.4 (s, C(CH3)3), 30.4 (s, C(CH3)3), 18.6 (s, CH3
xylyl), 18.5 (s, CH3
xylyl), 17.4 (s, 
CH3
ala.). IR: νmax (neat)/cm
-1: 3319 (NH), 3062 (NH), 2961 (CH), 1750 (C=O), 1582 
(carbene). 
 
Synthesis of [(C^N
pz
^C)Au{C(NHCH(
i
Pr)CO2Me)(NHC6H3Me2-2,6)}]SbF6 (8) 
L-valine methyl ester HCl (0.029 g, 0.175 mmol) was added to a flame-dried Schlenk flask 
charged with K2CO3 (0.012 g, 0.088 mmol) and acetonitrile (5 mL). The solution was 
sonicated for 30 min and transferred to a separate flame-dried Schlenk flask containing 2 
(0.079 g, 0.087 mmol). The mixture was stirred for 16 h at room temperature and the 
precipitate removed by filtration through a celite plug. Next, the solvent was removed under 
vacuum and the solid residue re-dissolved in dichloromethane (2 mL). The product was 
crashed out of solution using a 2:1 mixture of light petroleum (bp. 40-60 °C) / diethyl ether (5 
mL), and after removing the solvent, dried under vacuum to yield a bright yellow solid (0.068 
g, 75%). Anal. Calcd. for C39H48AuN4O2SbF6 (1037.56): C, 45.15; H, 4.66; N, 5.40. Found: 
C, 44.86; H, 4.52; N, 5.52. 1H NMR (CD3CN, 300 MHz, 298 K): δ 9.26 (s, 1H, NH), 8.80 (s, 
2H, H2), 7.62 (2d, 3J = 9.0 Hz, 2H, H5+5’), 7.80 (d, 4J = 1.89 Hz, 1H, H8), 7.53 (s, 1H, H8), 
7.25-7.28 (m, 4H, NH + H6+6’+8’), 7.13-7.24 (m, 3H, CHxylyl), 4.26 (m, 1H, NCH), 3.15 (s, 
3H, OCH3), 2.33 (s, 3H, CH3
xylyl), 2.30 (s, 3H, CH3
xylyl), 1.88 (m, 1H, CHiPr), 1.09 (s, 9H, 
tBu), 1.08 (s, 9H, tBu), 0.61 (d, 3JH-H = 6.9 Hz, 6H, CH3
iPr). 13C{1H} NMR (CD3CN, 75 
MHz): δ 177.7 (s, C10), 171.7 (s, C=O), 166.5 (s, C9), 165.6 (s, C9’), 157.9 (s, C7), 157.8 (s, 
C
7’), 157.4 (s, C4), 157.3 (s, C4’), 145.9 (s, C3), 145.8 (s, C3’), 140.7 (s, C2), 136.7 (s, Cxylyl), 
136.6 (s, Cxylyl), 134.6 (s, C8), 134.0 (s, C8’), 133.1 (s, CHxylyl), 130.7 (s, CHxylyl), 130.6 (s, 
CHxylyl), 127.9 (s, C5), 127.8 (s, C5’), 126.5 (s, C6), 126.2 (s, C6’), 69.5 (s, NCH), 53.2 (s, 
OCH3), 36.3 (s, C(CH3)3), 36.3 (s C(CH3)3), 32.3 (s, CH
iPr), 31.4 (s, C(CH3)3), 31.3 (s, 
C(CH3)3), 19.9 (s, CH3
xylyl), 19.7 (s, CH3
xylyl), 19.5 (s, CH3
iPr), 19.4 (s, CH3
iPr), 0.9 (s, CHiPr). 
IR: νmax (neat)/cm
-1: 3300 (NH), 3189 (NH), 2965 (CH), 1742 (C=O), 1582 (carbene). 
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 Synthesis of [(C^N
pz
^C)Au{C(NHCH(Ph)CO2Me)(NHC6H3Me2-2,6)}]SbF6 (9) 
D-phenylglycine methyl ester HCl (0.030 g, 0.146 mmol) was added to a flame-dried Schlenk 
flask charged with K2CO3 (0.012 g, 0.087 mmol), molecular sieves and acetonitrile (5 mL). 
The solution was sonicated for 30 min and transferred to a separate flame-dried Schlenk flask 
containing 2 (0.066 g, 0.073 mmol). The reaction was stirred for 16 h at room temperature 
and the precipitate removed from solution via filtration through a celite plug. The solvent was 
removed under vacuum and the solid residue re-dissolved in dichloromethane (2 mL). The 
product was crashed out of solution using a 2:1 mixture of light petroleum (bp. 40-60 °C) / 
diethyl ether (5 mL), and after removing the solvent, dried under vacuum to yield an orange 
solid (0.059 g, 0.055 mmol, 53 %). Calcd. for C42H46AuF6N4O2Sb.2CH2Cl2 (1241.4): C, 
42.57; H, 4.06; N, 4.51. Found: C, 42.55; H 4.03; N 4.15. 1H NMR (CD3CN, 300 MHz, 298 
K): δ 9.51 (s, 1H, NH), 9.02 (s, 1H, H2), 8.97 (s, 1H, H2’), 8.11 (d, 3JH-H = 6.0 Hz, 1H, NH), 
7.87 (d, 3JH-H = 8.2 Hz, 1H, H
5), 7.74 (d, 3JH-H = 8.2 Hz, 1H, H
5’), 7.68 (d, 4JH-H = 1.6 Hz, 1H, 
H8), 7.51 (dd, 3JH-H = 8.2 Hz, 
4
JH-H = 1.6 Hz, 1H, H
6), 7.41-7.30 (m, 4H, H6’ + CHxylyl), 7.28 
(d, 4JH-H = 1.6 Hz, 1H, H
8’), 7.21-7.06 (m, 5H, CHPhGly), 5.68 (d, 3JH-H = 6.0 Hz, 1H, NCH), 
3.54 (s, 3H, OCH3), 2.51 (s, 3H, CH3
xylyl), 2.43 (s, 3H, CH3
xylyl), 1.35 (s, 9H, tBu), 1.17 (s, 
9H, tBu). 13C{H} NMR (CD3CN, 75 MHz): δ 176.5 (s, C
10), 169.4 (s, C=O), 165.3 (s, C9), 
164.3 (s, C9’), 157.1 (s, C7), 156.5 (s, C7’), 156.4 (s, C4), 156.4 (s, C4’), 145.0 (s, C3), 144.4 (s, 
C
3’), 139.6 (s, C2), 139.6 (s, C2’), 135.7 (s, CAr.), 135.6 (s, CAr.), 134.7 (s, CAr.), 133.4 (s, C8), 
133.0 (s, C8’), 132.1 (s, CAr.), 130.0 (s, CHAr.), 129.7 (s, CHAr.), 129.6 (s, CHAr.), 129.4 (s, 
CHAr.), 129.0 (s, CHAr.), 128.3, (s, CHAr.), 127.1 (s, C5), 126.5 (s, C5’), 125.3 (s, C6), 125.0 (s, 
C
6’), 65.5 (s, NCH), 53.2 (s, OCH3), 35.3 (s, C(CH3)3), 35.1 (s, C(CH3)3), 30.4 (s, C(CH3)3), 
30.4 (s, C(CH3)3), 18.6 (s, CH3
xylyl), 18.5 (s, CH3
xylyl). IR: νmax (neat)/cm
-1: 3295 (NH), 3173 
(NH), 2963 (CH), 1744 (C=O), 1586 (carbene). 
 
Synthesis of [(C^N
pz
^C)Au{C(NHCH(CH2CH2SMe)CO2Me)(NHC6H3Me2-2,6)}]SbF6 
(10) 
L-methionine methyl ester HCl (0.035 g, 0.175 mmol) was added to a flame-dried Schlenk 
flask charged with K2CO3 (0.012 g, 0.087 mmol), molecular sieves and acetonitrile (5 mL). 
The solution was sonicated for 30 min and transferred to a separate flame-dried Schlenk flask 
containing 2 (0.079 g, 0.087 mmol). The reaction was then stirred for 16 h at room 
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temperature and the precipitate removed from solution via filtration through a celite plug. 
Next, the solvent was removed under vacuum and the solid residue re-dissolved in 
dichloromethane (2 mL). The product was crashed out of solution using a 2:1 mixture of light 
petroleum (bp. 40-60 °C) / diethyl ether (5 mL), and after removing the solvent, dried under 
vacuum to yield an orange solid (0.069 g, 74%). Anal. Calcd. for C39H48AuN4O2SSbF6 
(1069.6): C, 43.79; H, 4.52; N, 5.24. Found: C, 43.58; H, 4.37; N, 5.08. 1H NMR (CD2Cl2, 
300 MHz, 298 K): δ 8.85 (s, 2H, H2), 8.71 (s, 1H, NH), 8.29 (d, 3JH-H = 9.0 Hz, 1H, NH), 
7.74 – 7.62 (m, 4H, H5/8), 7.48 – 7.35 (m, 5H, H6 + Hxylyl), 5.00 (m, 1H, NCH), 3.60 (s, 3H, 
OCH3), 2.63 (s, 3H, CH3
xylyl), 2.52 (s, 3H, CH3
xylyl), 2.14 (m, 2H, SCH2), 1.66 (s, 3H, SCH3), 
1.36 (s, 9H, tBu), 1.33 (s, 9H, tBu), 1.14 (s, 2H, CHCH2). 
13C{1H} NMR (CD2Cl2, 75 MHz): 
δ 178.2 (s, C10), 170.6 (s, C=O), 165.8 (s, C9), 165.1 (s, C9’), 158.2 (s, C7), 158.0 (s, C7’), 
157.0 (s, C4), 156.9 (s, C4’), 144.7 (s, C3), 144.6 (s, C3’), 139.5 (s, C2), 139.4 (s, C2’), 136.3 (s, 
C
Ar.), 135.7 (s, CAr.), 134.0 (s, C8), 132.9 (s, C8’), 131.7 (s, CHAr.), 130.9 (s, CHAr.), 130.5 (s, 
CHAr.), 130.2 (s, CAr.), 127.3 (s, C5), 127.1 (s, C5’), 125.9 (s, C6), 125.8 (s, C6’), 61.6 (s, 
OCH3), 36.0 (s, NCH), 31.9 (s, CHCH2), 31.3 (s, C(CH3)3), 31.2 (s, C(CH3)3),30.4 (s, 
C(CH3)3), 30.1 (s, C(CH3)3), 19.4 (s, CH3
xylyl), 19.3 (s, CH3
xylyl), 18.9 (s, SCH2), 14.8 (s, 
SCH3). IR: νmax (neat)/cm
-1: 3304 (NH), 3169 (NH), 2960 (CH), 1744 (C=O), 1585 (carbene). 
 
Synthesis of (C^N
pz
^C)Au(NHPh) (11a) 
A mixture of 1 (0.050 g, 0.087 mmol) and KOtBu (0.012 g, 0.104 mmol) in a flame-dried 
Schlenk flask with molecular sieves under N2 atmosphere was dissolved in toluene (5 mL) 
and stirred at room temperature for 3 h. Distilled aniline (8.26 µL, 0.087 mmol) was added 
and the mixture stirred for a further 3 h. The solvent was removed under vacuum and the 
product dissolved in dichloromethane. The solution was filtered through celite and the 
solvent removed under vacuum. The solid residue was washed twice with light petroleum and 
dried under vacuum to yield a black solid (0.050 g, 91 %). Anal. Calcd. for C30H32AuN3 
(631.6): C, 57.05; H, 5.11; N, 6.65. Found: C, 57.17; H, 5.26; N, 6.55. 1H NMR (CD2Cl2, 300 
MHz, 298 K): δ 8.69 (s, 2H, H2), 7.60 (d, 3JH-H = 8.1 Hz, 2H, H
5), 7.41 (d, 3JH-H = 1.8 Hz, 2H, 
H8), 7.30 (dd, 3JH-H = 8.4 Hz, 
4
JH-H = 2.1 Hz, 2H, H
6), 7.01 (dd, 3JH-H = 6.75, 2H, CH
meta), 
6.80 (dd, 3JH-H = 7.8 Hz, 
4
JH-H = 1.2 Hz, 2H, CH
ortho), 6.58 (t, 3JH-H = 7.2, 1H, CH
para), 3.84 (s, 
1H, NH), 1.23 (s, 18H, tBu). 13C{1H} NMR (CD2Cl2, 75 MHz): δ 170.7 (s, C
9), 156.3 (s, C7 + 
C
4), 144.2 (s, C3), 138.4 (s, C2), 133.9 (s, C10),  131.5 (s, C8) 129.2 (s, Cipso), 125.6 (s, C5), 
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124.7 (s, C6), 120.0 (s, Cmeta,para), 117.1 (s, Cortho), 36.6 (s, C(CH3)3), 31.3 (s, C(CH3)3). IR: 
νmax (neat)/cm
-1: 3315 (NH), 2951 (CH). 
 
Synthesis of (C^N
pz
^C)Au(NHC6H3
i
Pr2-2,6)}] (11b) 
The procedure for 11a was followed to make 11b from 1 (0.050 g, 0.087 mmol), KOtBu 
(0.024 g, 0.218 mmol) and distilled 2,6-diisopropylaniline (0.015 g, 0.087 mmol). The 
solvent was removed under vacuum and the product dissolved in dichloromethane, filtered 
through celite and the solvent removed under vacuum to give an oily precipitate which was 
recrystallized from dichloromethane/ light petroleum at -20 °C to yield a brown solid (0.046 
g, 74 %). Anal. Calcd. for C36H44AuN3 (715.7): C, 60.41; H, 6.20; N, 5.87. Found: C, 60.29; 
H, 6.27; N, 5.74. 1H NMR (CD2Cl2, 300 MHz, 298 K): δ 8.81 (s, 2H, H
2), 7.65 (d, 3JH-H = 8.1 
Hz, 2H, H5), 7.28 (dd, 3JH-H = 8.1 Hz, J = 2.0 Hz, 2H, H
6), 7.13 (d, J = 7.6 Hz 2H, CHmeta), 
7.02 (m, 3H, H8 CHpara), 4.12 (s, 1H, NH), 3.69 (h, 3JH-H = 6.9 Hz, 2H, CH
iPr) 1.23 (s, 18H, 
tBu), 1.15 (d, 3JH-H = 6.9 Hz, 12H, CH3
iPr). 13C{1H} NMR (CD2Cl2, 75 MHz): δ 169.6 (s, C
9), 
156.4 (s, C7), 155.8 (s, C4), 148.4 (s, Cipso), 144.4 (s, C3), 141.8 (s, Cortho), 138.4 (s, C2), 129.3 
(s, CHmeta), 125.3 (s, C5), 124.2 (s, C8), 123.7 (s, C6), 121.9 (s, CHpara), 35.5 (s, C(CH3)3), 
31.1 (s, C(CH3)3), 28.2 (s, CH
iPr), 23.0 (s, CH3
iPr). IR: νmax (neat)/cm
-1: 3322 (NH), 2958 
(CH). 
 
Synthesis of (C^N
pz
^C)Au{C(NPh)(NHC6H3Me2-2,6)} (12) 
Product 11a (0.174 mmol) was made in-situ as described and, without prior purification, was 
treated with 2,6-dimethylphenyl isocyanide (0.023 g, 0.174 mmol). The mixture was stirred 
for 16 h. The solvent was removed under vacuum and the product dissolved in 
dichloromethane and filtered through Celite. The solvent removed again under vacuum to 
give a yellow oil which was washed with ice-cold hexane. The residue was dried under 
vacuum to yield a yellow solid (0.108 g, 83 %). Anal. Calcd. for C39H41AuN4 (762.8): C, 
61.41; H, 5.42; N, 7.35. Found: C, 61.44; H, 5.36; N, 7.25. 1H NMR (CD3CN, 300 MHz, 298 
K): δ 8.87 (s, 2H, H2), 8.05 (s, 2H, H8), 7.67 (d, 3JH-H = 8.4 Hz, 2H, H
5), 7.34 (dd, 3JH-H = 8.1 
Hz, 4JH-H = 2.1 Hz, 2H, H
6), 7.14-7.12 (m, 4H, CHAr.), 6.96-6.94 (m, 4H, CHAr.), 6.71 (s, 1H, 
NH), 2.52 (s, 6H, CH3
xylyl), 1.36 (s, 18H, tBu). 13C{1H} NMR (CD3CN, 75 MHz): δ 167.3 (s, 
C
9), 156.7 (s, C7), 156.5 (s, C4), 146.0 (s, C3), 139.8 (s, C2), 135.9 (s, C8), 130.7 (s, CAr.), 
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129.4 (s, CHAr.), 128.9 (s, CAr.), 127.0 (s, C5), 124.8 (s, C6), 124.7 (s, C10), 123.4 (s, CHAr.), 
36.0 (s, C(CH3)3), 31.5 (s, C(CH3)3), 20.0 (s, CH3
xylyl). IR: νmax (neat)/cm
-1: 3340 (NH), 2957 
(CH), 1607 (C=N). 
 
Synthesis of [(C^N
pz
^C)Au{C(NHPh)(NHC6H3Me2-2,6)}]BF4 (4·BF4) 
A solution of 12 (0.050 g, 0.067 mmol) in diethyl ether at -78 ºC was treated with HBF4·OEt2 
(9 µL, 0.067 mmol). There was an immediate colour change from yellow to orange. The 
mixture was allowed to warm to room temperature and left to stir for 30 min. The solvent was 
removed under vacuum to yield an orange powder (0.057 g, 99 %). Anal. Calcd. for 
C39H42AuN4BF43H2O (904.6): C, 51.78; H, 5.35; N, 6.19. Found: C, 51.23; H, 4.05; N, 6.25. 
1H NMR (CD3CN, 300 MHz, 298 K): δ 9.71 (s, 1H, NH), 9.47 (s, 1H, NH), 8.98 (s, 2H, H
2), 
7.82-7.79 (m, 4H, CHAr.), 7.48-7.37 (m, 7H, CHAr.), 7.24-7.17 (m, 3H, CHAr.), 2.55 (s, 6H, 
CH3
xylyl), 1.36 (s, 18H, tBu). 13C{1H} NMR (CD3CN, 75 MHz): δ 176.2 (s, C
10), 165.8 (s, 
C
9), 157.8 (s, C7), 157.4 (s, C4), 145.7 (s, C3), 140.6 (s, C2), 139.9 (s, CAr.), 136.6 (s, CAr.), 
134.1 (s, C8), 133.5 (s, CAr.), 130.9 (s, CHAr.), 130.6 (s, CHAr.), 130.5 (s, CHAr.), 128.8 (s, 
CHAr.), 127.7 (s, C5), 126.1 (s, C6), 124.9 (s, CHAr.), 36.3 (s, C(CH3)3), 31.4 (s, C(CH3)3), 
19.4 (s, CH3
xylyl). IR: νmax (neat)/cm
-1: 3215 (NH), 2956 (CH), 1586 (carbene). 
 
X-ray crystallography 
Pale-yellow square plates of 2 were grown by slow evaporation of a saturated solution of the 
crude product in CH2Cl2. Complex 3 was crystallized by slow diffusion of light petroleum in 
a saturated solution of the complex in CH2Cl2. Yellow square plates with stoichiometry 5·1.5 
toluene were grown by diffusion of petroleum into a saturated solution of the complex in 
toluene. Crystals of 6 and 11a were grown by the slow evaporation of saturated 
dichloromethane solutions. Slow diffusion of light petroleum into a saturated solution of 12 
produced yellow needles with stoichiometry 12·toluene. The crystals were mounted on a 
MiTeGen MicroMesh and fixed in a cold nitrogen stream. Diffraction intensities were 
recorded at 298, 173 or 140 K on a Rigaku HG Saturn724+ (2×2 bin mode) diffractometer or 
an Oxford Diffraction Xcalibur-3 instrument, both equipped with Mo-Kα radiation. Data 
collection, refinement and reduction were performed using the CrystalClear-SM Expert 3.1 
b27 or CrysAlisPro software and the absorption correction was applied at this stage.38 All 
structures were solved using SHELXS/T and refined by full-matrix least-squares methods on 
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F2 with SHELXL.39 Non-hydrogen atoms were refined with anisotropic thermal parameters. 
Hydrogen atoms were included in idealised positions. No missed symmetry was reported by 
PLATON.40 Computer programs used in this analysis were run through WinGX.41 Scattering 
factors for neutral atoms were taken from reference.42  
 
Antiproliferation assay  
The human A549 and HL60 cancer cell lines (from ECACC) were cultured in RPMI 1640 
medium with 10% fetal calf serum, 2mM L-glutamine, 100U/mL penicillin and 100 µg/mL 
streptomycin (Invitrogen). Cells were maintained in a humidified atmosphere at 37°C and 5% 
CO2. The human MCF-7, HCT116 and MDA-MB-231 cancer cell lines (from ECACC) and 
the healthy fibroblasts MRC-5 cells were cultured in DMEM medium with 10% fetal calf 
serum, 2mM L-glutamine, 100U/mL penicillin and 100 µg/mL streptomycin (Invitrogen). 
Cells were maintained in a humidified atmosphere at 37 °C and 5% CO2. Inhibition of cancer 
cell proliferation was measured by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay using the CellTiter 
96 Aqueous One Solution Cell Proliferation Assay (Promega) and following the 
manufacturer’s instructions. Briefly, cells (3 × 104/100 µL for HL-60, 8 × 103/100 µL for 
A549, MCF-7, HCT116, MDA-MB-231 and 2 × 103/100 µL for MRC-5) were seeded in 96-
well plates and left untreated or treated with 1 µL of DMSO (vehicle control) or 1 µL of 
complexes diluted in DMSO at different concentrations, in triplicate for 72 h at 37 °C with 
5% CO2. Following this, MTS assay reagent was added for 4 h and absorbance measured at 
490nm using a Polarstar Optima microplate reader (BMG Labtech). IC50 values were 
calculated using GraphPad Prism Version 5.0 software.  
 
ROS assay 
100 µL of A549 cells were seeded at a density of 1 × 105 cells/mL in a 96-well black plate 
with a transparent bottom. The cells were incubated at 37 °C for 24 h. The medium was 
removed, and replaced with 50 µM H2DCFDA (from Life Technologies) solution in PBS for 
40 min. H2DCFDA was removed and replaced with fresh medium. The cells were left for 
recovery for 20 min at 37°C. Basal fluorescence was measured at 485/520 nm on a 
POLARstar Optima. Cells were incubated with 10 µM, 50µM, or 100 µM of compounds, 1% 
DMSO (negative control) and 100 µM of H2O2 (positive control) for 24 h. Fluorescence was 
read at 485/520 nm. Basal fluorescence was subtracted from the fluorescence in treated cells 
to calculate the amount of fluorescence caused by the compounds. 
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